Solulink, Inc., inventor and developer of novel biomolecular conjugation chemistries, today announced that the U.S.Patent & Trademark Office has issued U.S. Patent No. 6,686,461 “Triphosphate Oligonucleotide Modification Reagents and Uses Thereof”. The patent covers composition of matter and use of this new type of modified capture nucleoside triphosphate that incorporates Solulink’s hydrazine/carbonyl conjugation technology for labeling cDNA and RNA from in vitro transcription reactions. The new capture nucleoside triphosphate is much easier to use, significantly more cost effective as it requires fewer steps to isolate labeled nucleotide and uses 5 to 10 times less fluorophore.
